These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Discordant growth hormone and IGF-1 levels post pituitary surgery in patients with acromegaly naïve to medical therapy and radiation: what to follow, GH or IGF-1 values? Brzana JA, Yedinak CG, Delashaw JB, Gultelkin HS, Cook D, Fleseriu M. Pituitary; 2012 Dec; 15(4):562-70. PubMed ID: 22183781 [Abstract] [Full Text] [Related]
4. Impact of tumor characteristics and pre- and postoperative hormone levels on hormonal remission following endoscopic transsphenoidal surgery in patients with acromegaly. Cardinal T, Rutkowski MJ, Micko A, Shiroishi M, Jason Liu CS, Wrobel B, Carmichael J, Zada G. Neurosurg Focus; 2020 Jun; 48(6):E10. PubMed ID: 32480366 [Abstract] [Full Text] [Related]
10. Low insulin resistance after surgery predicts poor GH suppression one year after complete resection for acromegaly: a retrospective study. Edo N, Morita K, Suzuki H, Takeshita A, Miyakawa M, Fukuhara N, Nishioka H, Yamada S, Takeuchi Y. Endocr J; 2016 May 31; 63(5):469-77. PubMed ID: 26949262 [Abstract] [Full Text] [Related]
11. Discordant GH and IGF-1 Results in Treated Acromegaly: Impact of GH Cutoffs and Mean Values Assessment. Campana C, Cocchiara F, Corica G, Nista F, Arvigo M, Amarù J, Rossi DC, Zona G, Ferone D, Gatto F. J Clin Endocrinol Metab; 2021 Mar 08; 106(3):789-801. PubMed ID: 33236108 [Abstract] [Full Text] [Related]
12. Ghrelin test for the assessment of GH status in successfully treated patients with acromegaly. Pekic S, Doknic M, Miljic D, Joksimovic M, Glodic J, Djurovic M, Dieguez C, Casanueva F, Popovic V. Eur J Endocrinol; 2006 May 08; 154(5):659-66. PubMed ID: 16645012 [Abstract] [Full Text] [Related]
13. Long-term control of acromegaly after pituitary surgery in South-Eastern Norway. Falch CM, Dupont AK, Olarescu NC, Wiedmann M, Dahlberg D, Bollerslev J, Berg-Johnsen J, Heck A. Acta Neurochir (Wien); 2023 Oct 08; 165(10):3003-3010. PubMed ID: 37665404 [Abstract] [Full Text] [Related]
14. Clinical indicators of biochemical remission in acromegaly: does incomplete disease control always mean therapeutic failure? Damjanovic SS, Neskovic AN, Petakov MS, Popovic V, Macut D, Vukojevic P, Joksimovic MM. Clin Endocrinol (Oxf); 2005 Apr 08; 62(4):410-7. PubMed ID: 15807870 [Abstract] [Full Text] [Related]
15. Radiosurgery of growth hormone-producing pituitary adenomas: factors associated with biochemical remission. Pollock BE, Jacob JT, Brown PD, Nippoldt TB. J Neurosurg; 2007 May 08; 106(5):833-8. PubMed ID: 17542527 [Abstract] [Full Text] [Related]
16. Postoperative GH and Degree of Reduction in IGF-1 Predicts Postoperative Hormonal Remission in Acromegaly. Cardinal T, Collet C, Wedemeyer M, Singer PA, Weiss M, Zada G, Carmichael JD. Front Endocrinol (Lausanne); 2021 May 08; 12():743052. PubMed ID: 34867787 [Abstract] [Full Text] [Related]
18. Preoperative growth hormone response to thyrotropin-releasing hormone and oral glucose tolerance test in acromegaly: a retrospective evaluation of 50 patients. De Marinis L, Mancini A, Bianchi A, Gentilella R, Valle D, Giampietro A, Zuppi P, Anile C, Maira G, Giustina A. Metabolism; 2002 May 08; 51(5):616-21. PubMed ID: 11979395 [Abstract] [Full Text] [Related]
20. Pure endoscopic transsphenoidal surgery for treatment of acromegaly: results of 67 cases treated in a pituitary center. Gondim JA, Almeida JP, de Albuquerque LA, Gomes E, Schops M, Ferraz T. Neurosurg Focus; 2010 Oct 08; 29(4):E7. PubMed ID: 20887132 [Abstract] [Full Text] [Related] Page: [Next] [New Search]